Biocon gains as its arm enters into partnership with Adagio Therapeutics

27 Jul 2021 Evaluate

Biocon is currently trading at Rs. 392.50, up by 3.05 points or 0.78% from its previous closing of Rs. 389.45 on the BSE.

The scrip opened at Rs. 396.20 and has touched a high and low of Rs. 396.20 and Rs. 391.30 respectively. So far 18387 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 363.30 on 01-Feb-2021.

Last one week high and low of the scrip stood at Rs. 408.00 and Rs. 387.90 respectively. The current market cap of the company is Rs. 46757.37 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 23.43% and 15.93% respectively.

Biocon’s subsidiary -- Biocon Biologics has entered into partnership with U.S. based Adagio Therapeutics to manufacture and commercialize an antibody treatment based on ADG20 for India and select emerging markets.

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

365.25 -1.15 (-0.31%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×